No Data
No Data
Hong Kong stocks are volatile | Lai Kai Pharmaceutical-B (02105) surged more than 10% in the afternoon, and ActRIIA monoclonal antibody LAE102 for the treatment of obesity has been clinically approved in China and the United States.
In the afternoon, Lai Kai Medicine-B (02105) rose more than 10%, as of the time of publication, up 4.79%, at HKD 5.03, with a turnover of HKD 10.6549 million.
The enrollment of AFFIRM-205 patients is progressing smoothly. The phase III clinical trial of breast cancer by Laike Medicine (2105.HK) is highly anticipated.
On July 2nd, 2024, the phase III study "Evaluation of the effectiveness and safety of Afuresertib+fluvisine in locally advanced or metastatic HR+/HER2- breast cancer patients who failed standard treatment" (AFFIRM-205) led by academician Xu Binghe of Cancer Hospital, Chinese Academy of Medical Sciences will be held in Beijing on June 23. More than 50 breast cancer experts from 47 tumor research centers across the country jointly reviewed the safety and effectiveness data of the previous studies and held in-depth discussions on the research plan and implementation strategy of the phase III clinical trial.
"Muscle gain and fat loss" becomes a new trend in the tens of billions of weight loss market, attracting attention with the cooperation between Kalbe Pharma-B (02105) and Novo Nordisk on muscle gain and fat loss research.
With the mutual efforts with Novo-Nordisk, Laike Pharmaceutical is expected to become a frontrunner in the global weight loss market worth hundreds of billions, and achieve a leap in its own valuation in the future.
Laekna Administers First Dose of Weight Loss Drug in China During Phase I Clinical Trials; Shares Gain 6%
Laekna (HKG:2105) disclosed that the first patient was administered a dose of LAE102, a weight loss drug, during the Phase I clinical trial in China, according to a Wednesday filing on the Hong Kong b
LAE102 completed the first dose in Phase I clinical trial for obesity treatment at Laike Pharmaceutical-B (02105.HK).
On June 26th, Gelunhui announced that the group had launched the recruitment of Phase I clinical trials of LAE102 in China and completed the first subject's medication. The Phase I clinical trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of this therapy. The group is committed to bringing this precision treatment to overweight and obese patients who need new treatment options to achieve high-quality weight control.
Hong Kong stocks move | Lai Kai medicine-B (02105) rose more than 12%, with multiple catalysts in the core pipeline, and the research and development of the "muscle gain and fat loss" pipeline is accelerating.
Lai Kai Medicine-B (02105) rose highest by more than 12%, as of press time, up 10.9%, at HKD 5.9, with a turnover of HKD 4.324 million.
No Data